Expertise in
5
conditions

Fabio Benedetti

Policlinico G.B. Rossi
Verona, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Policlinico G.B. Rossi
Verona, IT 

Overview

Fabio Benedetti practices practicing medicine in Verona, Italy.

Mr. Benedetti is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 70 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Policlinico G.B. Rossi
Verona, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Consolidation With ADCT-402 (Loncastuximab Tesirine) After a Short Course of Immunochemotherapy: a Phase II Study in BTKi-treated (or BTKi Intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients
Consolidation With ADCT-402 (Loncastuximab Tesirine) After a Short Course of Immunochemotherapy: a Phase II Study in BTKi-treated (or BTKi Intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients
Enrollment Status: Recruiting
Publish Date: January 05, 2026
Intervention Type: Drug
Study Drug: Consolidation with ADCT-402 (Loncastuximab Tesirine) After Salvage Immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C))
Study Phase: Phase 2
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Enrollment Status: Completed
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Study Phase: Phase 2
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Enrollment Status: Completed
Publish Date: December 08, 2025
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 2
Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drugs: Romidepsin, CHOEP-21
Study Phase: Phase 1/Phase 2
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
A Phase II, Open Label, Multicenter Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in Patients With Relapsed/Refractory CD38 Positive Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal Lymphomas of TFH Cell Origin
A Phase II, Open Label, Multicenter Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in Patients With Relapsed/Refractory CD38 Positive Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal Lymphomas of TFH Cell Origin
Enrollment Status: Terminated
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: Daratumumab
Study Phase: Phase 2
A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
Enrollment Status: Unknown
Publish Date: December 14, 2023
Intervention Type: Drug, Other
Study Drug: BEAM
Study Phase: Phase 3
Carfilzomib (K) Plus Lenalidomide (R) and Dexamethasone (D) for BTK Inhibitors Relapsed-refractory or Intolerant Mantle Cell Lymphomas: a Phase II Study
Carfilzomib (K) Plus Lenalidomide (R) and Dexamethasone (D) for BTK Inhibitors Relapsed-refractory or Intolerant Mantle Cell Lymphomas: a Phase II Study
Enrollment Status: Unknown
Publish Date: September 15, 2022
Intervention Type: Drug
Study Drugs: Carfilzomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Genetic, Other
Study Phase: Phase 3
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Enrollment Status: Completed
Publish Date: July 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

70 Total Publications

GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.
Journal: Haematologica
Published: August 04, 2025

Frequently Asked Questions about Fabio Benedetti

Is Fabio Benedetti a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Fabio Benedetti is classified as an Advanced expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Fabio Benedetti participate in research or clinical trials?

Yes. Fabio Benedetti has published 70 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Fabio Benedetti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Benedetti's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile